Compare WOR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | TRVI |
|---|---|---|
| Founded | 1955 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 1998 | 2019 |
| Metric | WOR | TRVI |
|---|---|---|
| Price | $60.84 | $14.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $59.50 | $21.55 |
| AVG Volume (30 Days) | 409.3K | ★ 1.4M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 63.54 | 31.91 |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $1,381,292,000.00 | N/A |
| Revenue This Year | $22.21 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $19.39 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $45.01 | $8.99 |
| 52 Week High | $67.54 | $20.22 |
| Indicator | WOR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 30.29 |
| Support Level | $52.34 | $13.08 |
| Resistance Level | $63.13 | $14.75 |
| Average True Range (ATR) | 2.67 | 0.56 |
| MACD | 0.28 | -0.07 |
| Stochastic Oscillator | 49.35 | 15.56 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.